Mutations in the human immunodeficiency virus type 1 reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages

Research in Virology

Volumn 149, Issue 6, 1998, Pages 355-361

  Bossi, P ^a   Yvon, A ^a   Mouroux, M ^a   Huraux, J M ^a   Agut, H ^a   Calvez, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Didanosine; Resistance; HIV; Stavudine

Indexed keywords

DIDANOSINE; STAVUDINE;

ARTICLE; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOBLASTOID CELL LINE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STRAIN DIFFERENCE; VIRUS MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032209142     PISSN: 09232516     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-2516(99)80003-X     Document Type: Article

References (29)

1. Bloor, S., Hertogs, K., Desmer, R.L., Pauwels, R. & Larder, B.A. (1998), Virological basis for HIV 1 resistance to stavudine investigated by analysis of clinical samples. Antiviral Therapy, 3 (suppl. 1), 13-14.
2. Brun-Vézinet, F., Ingrand, D., Deforges, L., Gochi, K., Ferchal, F., Schmitt, M., Jung, M., Masquelier, B., Aubert, J., Buffet-Janvresse, C. & Fleury, H. (1992), HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J. Virol. Methods, 37, 177-188.
3. De Jong, J.J., Jurriaans, S., Goudsmit, J., Baan, E., Huismans, R., Danner, S., Hillebrand, M., Ten Veen, J.H. & De Wolf, F. (1998), Insertion of two amino acids in reverse transcriptase (RT) during antiretroviral combination therapy: implications for resistance against nucleoside RT inhibitors. Antiviral Therapy, 3 (suppl. 1), 15.
4. Fitzgibbon, J.E., Howell, R., Haberzetti, C.A., Sperber S.J., Gocke D.J. & Dubin D.T. (1992), Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother., 36, 153-157.
5. Gao, Q., Gu, Z., Parniak, A., Li, X. & Wainberg, M. (1992), In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythyrnidine and 2′, 3′-dideoxyinosine. J. Virol., 66, 12-19.
6. Gao, Q., Gu, Z.X., Parniak, M.A., Cameron, J., Cammack, N., Boucher, C. & Wainberg, M. (1993), The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother., 37, 1390-1392.
7. Gu, Z., Gao, Q., Li, X., Parniak, M.A. & Wainberg, M.A. (1992), Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol., 66, 7128-7135.
8. Gu, Z., Gao, Q., Fang, H., Salomon, H., Parniak, M., Goldberg, E., Cameron, J. & Wainberg, M. (1994a), Identification of a mutation at codon 65 in the IKKC motif of reverse transcriptase that encodes HIV resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother., 38, 275-281.
9. Gu, Z., Gao, Q., Fang, H., Parniak, M.A., Brenner, E.G. & Wainberg, M.A. (1994b), Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia, 8 (suppl. 1), 5166-5169.
10. Harada, S., Koyanagi, Y. & Yamamoto, N. (1985), Infection of HTLV-III/LAV in HTLV-I carrying cells MT2 and MT4 and application in a plaque assay. Science, 229, 563-566.
11. Iversen, A.K., Shafer, R.W., Wehrly, K., Winters, M., Mullins, J., Chesebro, B. & Merigan, T. (1996), Multidrug-resistant human immunodeficiency virus type-1 strains resulting from combinaison antiretroviral therapy. J. Virol., 70, 1086-1099.
12. Kellam, P., Boucher, C.A. & Larder, B.A. (1992), Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Nat. Acad. Sci. USA, 89, 1934-1938.
13. Lacey, S.F. & Larder, B.A. (1994), Novel mutation (V75T) in human immunodeficiency virus type reverse transcriptase confers resistance to 2′,3′-didehydro-2′, 3′-dideoxythymidine in cell culture. Antimicrob. Agents Chemother., 38, 1428-1432.
14. Larder, B.A. & Kemp, S.D. (1989), Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science, 246, 1155-1158.
15. Larder, B.A., Coates, K.E. & Kemp, S.D. (1991), Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J. Virol., 65, 5232-5236.
16. Larder, B.A., Kellam, P. & Kemp, S.D. (1993), Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature, 365, 451-453.
17. Lin, P.F., Samanta, H., Rose, R.E., Patick, A.K., Trimble, J., Betchold, C.M., Revie, D.R., Khan, N.C., Federici, M.E., Li, H., Lee, A., Anderson, R.E. & Colonno, R.J. (1994), Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect. Dis., 170, 1157-1164.
18. Moyle, G.J. (1996), Use of viral resistance patterns to antiretroviral drugs in optimizing selection of drug combinations and sequences. Drugs, 52, 168-185.
19. Pollard, R., Peterson, D., Hardy, D., Pedneault, L., Rutkiewicz, V., Pottage, J., Murphy, R., Gathe, J., Beall, G., Skovronski, J., Cross, A. & Dunkle, L. (1996), Stavudine and didanosine combination therapy in HIV-infected subjects: antiviral effect and safety in an on-going pilot randomized double-bind trial, in "XIth International Conference on AIDS", Vancouver, Th B 293.
20. St Clair, M.H., Martin, J.L., Tudor-Williams, G., Bach, M.C., Vavro, C.L., King, D.M., Kellam, P., Kemp, S.D. & Larder, B.A. (1991), Resistance to ddI and sensitivity to AZT induced by a mutation in HPV-1 reverse transcriptase. Science, 253, 1557-1559.
21. Schinazi, R.F., Lloyd, R.J., Nguyen, M.H., Cannon, D.L., McMillan, A., Ilksoy, N., Chu, C.K., Liotta, D.C., Bazmi, H.Z. & Mellors, J.W. (1993), Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother., 37, 875-881.
22. Schinazi, R.F., Larder, B.A. & Mellors, J.W. (1997), Mutations in retroviral genes associated with drug resistance. Int. Antivir. News, 5, 1-14.
23. Schuurman, R., Nijhuis, M., Van Leeuwen, R., Schipper, P., De Jong, D., Collis, P., Danner, S., Mulder, J., Loveday, C., Christopherson, C., Kwok, S., Sninsky, J. & Boucher, C. (1995), Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis., 171, 1411-1419.
24. Shirasaka, T., Kavlick, M.F., Ueno, T., Gao, W.Y., Kojima, E., Alcaide, M.L., Chokekijchal, S., Roy, B.M., Arnold, E. & Yarchoan, R. (1995), Emergence of human immunodeficiency virus type-1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Nat. Acad. Sci. USA, 92, 1-5.
25. Slade, D.E., Vavro, C.L., Stapelton, J.T., Swack, N. & St Clair, M.H. (1993), A cysteine at codon 215 of HIV RT confers resistance to ddC, in "Second International HIV-1 Drug resistance Workshop", Noordwijk, The Netherlands.
26. Tinsdale, M., Kemp, S.D., Parry, N.R. & Larder, B.A. (1993), Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Nat. Acad. Sci. USA, 90, 5653-5656.
27. Wain-Hobson, S., Sonigo, P., Danos, O., Cole, S. & Alizon, M. (1985), Nucleotide sequence of the AIDS virus, LAV. Cell, 40, 9-17.
28. Whitcomb, J.M., Limoli, K., Wrin, T., Smith, D., Tian, H., Parkin, N., Lie, Y.S. & Petropoulos, C.J. (1998), Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1. Antiviral Therapy, 3 (suppl. 1), 14-15.
29. Winter, M.A., Coolley, K.L., Girard, Y.A., Levee, D.J., Hamdan, H., Katzenstein, D.A., Shafer, R.W. & Merigan, T.C. (1998), Phenotypic and molecular analysis of HIV-1 isolates possessing 6 bp inserts in the reverse transcriptase gene that confer resistance to nucleoside analogues. Antiviral Therapy, 3 (suppl. 1), 14.